Predictive value of pretransplantation cyclosporine pharmacokinetic studies on initial post-transplantation dosing in pediatric kidney allograft recipients

Pediatric Transplantation

Volumn 7, Issue 2, 2003, Pages 102-110

  Seikku, Paula ^a   Hoppu, Kalle ^a   Jalanko, Hannu ^a   Holmberg, Christer ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cyclosporine; Pediatric kidney transplantation; Pharmacokinetic studies

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ADOLESCENT; ARTICLE; CHILD; CREATININE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INFANT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; SIDE EFFECT;

ADOLESCENT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 0037396946     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2003.00025.x     Document Type: Article

References (43)

1. PERICO N, REMUZZI G. Prevention of transplant rejection: current treatment guidelines and future developments. Drugs 1997: 54: 533-570.
2. CHARPENTIER B, HIESSE Ch, DURRBACH A, et al. Overview of clinical trials with new agents. Transplant Proc 2001: 33: 2201-2203.
3. SEIKALY M, HO PL, EMMETT L, TEJANI A. The 12th annual report of the North American Pediatric Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Pediatr Transplant 2001: 5: 215-231.
4. TSUNODA SM, AWEEKA FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996: 30: 107-140.
5. MYERS B, ROSS J, NEWTON L, LUETSCHER J, PERLRATH M. Cyclosporin-associated nephropathy. N Engl J Med 1984: 311: 699-705.
6. NOBLE S, MARKHAM A. Cyclosporin: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®). Drugs 1995: 50: 924-941.
7. PTACHCINSKI RJ, VENKATARAMANAN R, BURCKART GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986: 1 1: 107-132.
8. COONEY GF, HABUCKY K, HOPPU K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997: 32: 481-495.
9. OELLERICH M, ARMSTRONG VW, KAHAN B, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995: 17: 642-654.
10. CHAVERS BM, MATAS AJ, GILLINGHAM KJ, SCHMIDT WJ, NAJARIAN JS. Pediatric renal transplantation at the University of Minnesota: the cyclosporine years. In: TERASAKI Pl, CECKA JM, eds. Clinical Transplants 1994. Los Angeles: UCLA Tissue Typing Laboratory, 1994, p. 203.
11. SOIN AS, RASMUSSEN A, JAMIESON NV. et al. CsA levels in early posttransplant period - predictive of chronic rejection in liver transplantation? Transplantation 1995: 59: 1119-1123.
12. TEJANI A, SULLIVAN EK. The impact of acute rejections on chronic rejection: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2000: 4: 107-111.
13. LINDHOLM A, DAHLQVIST R, GROTH G, SJÖQVIST F. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Brit J Clin Pharmacol 1990: 30: 443-452.
14. COONEY GF, HEIFETS M, BELL A, SHAW LM, LIBETTI G. Utility of pretransplantation cyclosporine pharmacokinetic studies. Ther Drug Monit 1994: 16: 151-154.
15. LOCKIE F, FISCHER A. GLUCKMAN E. A safer approach to the clinical use of cyclosporine: the predose calculation. Transplant Proc 1986: 18 (Suppl. 5): 194-199.
16. KESTILÄ M, LENKKERI U, MÄNIKÖ M, et al. Positionally cloned gene for a novel glomerular protein, nephrin, is mutated in congenital nephrotic syndrome. Mol Cell 1998: 1: 575-582.
17. BARONE G, CHANG CT, CHOC MG Jr., et al. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. Transplantation 1996: 61: 875-880.
18. HOLT DW, MUELLER EA, KOVARIK JM, VAN BREE JB, KUTZ K. The pharmacokinetics of Sandimmun Neoral: a new oral Formulation of cyclosporine. Transplant Proc 1994: 26: 2935-2939.
19. HOPPU K, KOSKIMIES O, HOLMBERG C, HIRVISALO EL. Evidence for pre-hepatic metabolism of oral cyclosporine in children. Brit J Clin Pharmacol 1991: 32: 477-481.
20. CAMPANA C, REGAZZI MB, BUGGIA I, MOLINARO M, Clinically significant drug interactions with cyclosporine. An update. Clin Pharmacokinet 1997: 30: 141-179.
21. GIBALDI M. Biopharmaceutics and Clinical Pharmacokinetics. 3rd edn. Philadelphia: Lea and Febiger, 1984.
22. Hoppu K, KOSKIMIES O, HOLMBERG C. HIRVISALO EL. Pharmacokinetically determined cyelosporine dosage in young children. Pediatr Nephrol 1991: 5: 1-4.
23. ETTENGER RB. Age and the immune response in pediatric renal transplantation. Eur J Pediatr 1992: 151 (Suppl. 1): S7-S8.
24. GREVEL J. Optimisation of immunosuppressive therapy using pharmacokinetic principles. Clin Pharmacokinet 1992: 23: 380-390.
25. REMUZZI G, PERICO N, GASPARI F. Optimization of cyclosporine therapy in kidney transplantation. Transplant Proc 1998: 30: 1673-1676.
26. MAHALATI K, BELITSKY P, SKETRIS I, WEST K, PANEK R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 1999: 68: 55-62.
27. LINDHOLM A, KAHAN BD. Influence of cyctosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993: 54: 205-218.
28. NANKIVELL BJ, HIBBIN SM, CHAPMAN JR. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 1994: 58: 989-996.
29. AMANTE AJ, KAHAN BD. Abbreviated area under the curve strategy for monitoring cyclosporine therapy in the immediate posttransplant period. Clin Chem 1996: 42: 1294-1296.
30. KASISKE BL, JOHNSON HJ, GOERDT PJ, et al. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients. Am J Kidney Dis 1997: 30: 639-645.
31. BRODEHL J. Cyclosporine therapy for transplantation in pediatric patients: consensus statements on the optimal use of cyclosporine in pediatric patients. Transplant Proc 1994: 26: 2759-2762.
32. OHLMAN S, LINDHOLM A, HÄGGLUND H, SÄWE J, KAHAN BD. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993: 44: 265-269.
33. ODLIND B, LINDBERG A, TUFVESON G, et al. Longitudinal study of the pharmacokinetics of cyclosporine before and after renal transplantation. Transplant Proc 1986: 18: 47-49.
34. FAHR A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993: 24: 472-495.
35. THEIR M, VON WILLEBRAND E, TASKINEN E, RÖNNHOLM K, HOLMBERG C, JALANKO H. Fine-needle aspiration biopsy allows early detection of acute rejection in children after renal transplantation. Transplantation 2001: 71: 736-743.
36. QVIST E, LAINE J, RÖNNHOLM K, JALANKO H, LEIJALA M, HOLMBERG C. Graft function 5-7 years after renal transplantation in early childhood. Transplantation 1999: 67: 1043-1049.
37. KOUWENHOVEN EA, DE BRUIN RWF, HEEMANN UN, MARQUET RL, IJERMANS JNM. Late graft dysfunction after prolonged cold ischemia of the donor kidney. Transplantation 1999: 68: 1004-1010.
38. MATAS AJ, GILLINGHAM KJ, CHAVERS BM, et al. The importance of early cyclosporine levels in pediatric kidney transplantation. Clin Tranplant 1996: 10 (6 Pt. 1): 482-486.
39. SALVATIERRA O JR., ALEXANDER SR, KRENSKY AM. Pediatric transplant grand rounds, Pediatric kidney transplantation at Stanford. Pediatric Tranplant 1998: 2: 165-176.
40. QVIST E, KROGERUS L, RÖNNHOLM K, LAINE J, JALANKO H, HOLMBERG C. Course of renal allograft histopathology after transplantation in early childhood. Transplantation 2000: 70: 1-7.
41. TEJANI A. A randomized prospective multicenter trial of T-cell antibody induction therapy in pediatric renal transplantation. Pediatr Nephrol 2000: 14: C44.
42. COLE EH. Neoral monitoring: limitations of trough level monitoring and the potential role of limited sampling strategies. Transplant Proc 2000: 32: 1556-1558.
43. BELITSKY P, DUNN S, JOHNSTON A, LEVY G. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet 2000: 39: 117-125.